aTYR Pharma (ATYR) awards director Paul Schimmel 50,000 stock options at $0.95

Rhea-AI Filing Summary

aTYR Pharma reported that director Paul Schimmel received a grant of stock options as part of the company’s non-employee director compensation policy. The award covers 50,000 options to buy common stock at an exercise price of $0.95 per share, expiring on May 11, 2036.

The option vests in full on the earlier of May 11, 2027 or the company’s 2027 annual stockholders’ meeting, conditioned on his continued board service. Following this grant, Schimmel holds 50,000 stock options directly, and the filing does not show additional derivative holdings.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SCHIMMEL PAUL

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	50,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 50,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 50,000 options Exercise price: $0.95 per share Expiration date: May 11, 2036 +3 more

6 metrics

Options granted 50,000 options Stock Option grant on May 11, 2026

Exercise price $0.95 per share Conversion or exercise price of options

Expiration date May 11, 2036 Option term end date

Underlying shares 50,000 shares Common stock underlying the options

Post-grant derivative holdings 50,000 options Total derivative securities following transaction

Vesting date trigger May 11, 2027 Earlier of this date or 2027 annual meeting

Key Terms

Stock Option (right to buy), non-employee director compensation policy, exercise price, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

non-employee director compensation policy financial

"The option, granted pursuant to the Issuer's non-employee director compensation policy"

exercise price financial

"conversion_or_exercise_price: 0.9500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-05-11T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Board of Directors financial

"subject to the Reporting Person's continued service on the Board of Directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHIMMEL PAUL

(Last) (First) (Middle)

C/O ATYR PHARMA, INC.

10240 SORRENTO VALLEY ROAD, SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
aTYR PHARMA INC [ ATYR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.95	05/11/2026		A		50,000		(1)	05/11/2036	Common Stock	50,000	$0.00	50,000	D

Explanation of Responses:

1. The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.

	/s/ Nancy E. Denyes, as Attorney-in-Fact	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did aTYR Pharma (ATYR) disclose about director Paul Schimmel?

aTYR Pharma disclosed that director Paul Schimmel received a grant of stock options. He was awarded 50,000 options under the non-employee director compensation policy, providing the right to buy common stock at a set exercise price if vesting conditions are met.

How many aTYR Pharma stock options were granted to Paul Schimmel?

Paul Schimmel was granted 50,000 stock options. These options give him the right to purchase 50,000 shares of aTYR Pharma common stock once they vest, aligning his compensation with the company’s equity performance over time.

What is the exercise price and expiration date of Paul Schimmel’s ATYR options?

The granted options have an exercise price of $0.95 per share and expire on May 11, 2036. This means he can buy shares at $0.95, if vested, any time before the expiration date specified in the grant.

When do Paul Schimmel’s aTYR Pharma stock options vest?

The options vest in full on the earlier of May 11, 2027 or aTYR Pharma’s 2027 annual meeting of stockholders. Vesting is contingent on his continued service on the company’s Board of Directors through that vesting date.

Is Paul Schimmel’s ATYR option grant an open-market purchase or compensation award?

The grant is a compensation-related award, not an open-market purchase. It was issued under aTYR Pharma’s non-employee director compensation policy, reflecting standard equity-based pay for board service rather than a discretionary market transaction.

How many aTYR Pharma stock options does Paul Schimmel hold after this grant?

After this grant, Paul Schimmel holds 50,000 stock options directly. The Form 4 shows these options as his derivative holdings following the transaction, with no additional derivative positions listed in the filing excerpt.